Table 3. Subgroup analyses.
| Subgroup | No. ofStudies | Patients | FixedRR(95%CI) | RandomRR (95%CI) | I2 | FixedRD (95%CI) | RandomRD (95%CI) | I2 |
| Total | 15 | 6983 | 0.94(0.87 to 1.02) | 0.95(0.88 to 1.03) | 0% | −0.01(−0.03 to 0.01) | −0.02(−0.04 to 0.00) | 9% |
| <6 h | 15 | 5757 | 0.93(0.85 to 1.02) | 0.94(0.86 to 1.03) | 0% | −0.02(−0.04 to 0.00) | −0.02(−0.05 to 0.00) | 7% |
| 6–24 h | 15 | 6400 | 0.91(0.84 to 0.99) | 0.92(0.85 to 1.00) | 0% | −0.02(−0.04 to 0.00) | −0.03(−0.05 to 0.00) | 8% |
| Age of patients | ||||||||
| Children | 4 | 2345 | 0.92(0.74 to 1.14) | 0.55(0.21 to 1.45) | 63% | −0.01(−0.04 to 0.02) | −0.07(−0.16 to 0.03) | 73% |
| Adults | 11 | 4638 | 0.95(0.87 to 1.03) | 0.95(0.87 to 1.03) | 0% | –0.02(–0.05 to 0.01) | –0.02(–0.05 to 0.01) | 0% |
| <6 h | 11 | 3412 | 0.93(0.84 to 1.03) | 0.94(0.85 to 1.03) | 0% | –0.02(–0.06 to 0.01) | –0.02(–0.06 to 0.01) | 0% |
| 6–24 h | 11 | 4055 | 0.91(0.84 to 1.00) | 0.92(0.84 to 1.00) | 0% | –0.03(–0.06 to 0.00) | –0.03(–0.06 to 0.00) | 0% |
| Types of control fluids | ||||||||
| Crystalloid | 11 | 6741 | 0.95(0.88 to 1.04) | 0.95(0.87 to 1.04) | 5% | –0.01(–0.03 to 0.01) | –0.02(–0.05 to 0.02) | 38% |
| <6 h | 11 | 5515 | 0.94(0.86 to 1.03) | 0.94(0.86 to 1.04) | 3% | –0.01(–0.04 to 0.01) | –0.02(–0.06 to 0.02) | 38% |
| 6–24 h | 11 | 6158 | 0.92(0.85 to 1.00) | 0.92(0.85 to 1.00) | 0% | –0.02(–0.04 to 0.00) | –0.03(–0.06 to 0.01) | 40% |
| Gelofusine | 2 | 100 | 0.33(0.10 to 1.12) | 0.42(0.05 to 3.18) | 59% | –0.12(–0.24 to 0.00) | –0.13(–0.24 to – 0.02) | 0% |
| Starch | 6 | 169 | 0.91(0.62 to 1.32) | 0.93(0.65 to 1.33) | 0% | –0.04(–0.17 to 0.10) | –0.05(–0.18 to 0.09) | 0% |
| Concentrations of albumin | ||||||||
| 4%–5% | 10 | 3691 | 0.90(0.79 to 1.01) | 0.91 (0.80 to 1.04) | 7% | –0.02(–0.05 to 0.00) | –0.05(–0.09 to 0.00) | 32% |
| 20%–25% | 4 | 2676 | 0.97(0.86 to 1.09) | 0.98 (0.87 to 1.09) | 0% | –0.01(–0.04 to 0.03) | –0.01(–0.04 to 0.02) | 0% |
| <6 h | 4 | 1450 | 0.96(0.82 to 1.11) | 0.97(0.83 to 1.12) | 0% | –0.01(–0.06 to 0.03) | –0.02(–0.06 to 0.03) | 0% |
| 6–24 h | 4 | 2093 | 0.92(0.82 to 1.03) | 0.92 (0.82 to 1.03) | 0% | –0.03(–0.07 to 0.01) | –0.03(–0.07 to 0.01) | 0% |
| Endpoints | ||||||||
| ICUmortality | 6 | 3587 | 0.88(0.76 to 1.02) | 0.86 (0.64 to 1.14) | 40% | –0.02(–0.04 to 0.00) | –0.05(–0.10 to 0.00) | 58% |
| Hospitalmortality | 5 | 1322 | 0.88(0.76 to 1.02) | 0.89 (0.78 to 1.02) | 0% | –0.04 (–0.09 to 0.01) | –0.04(–0.09 to 0.01) | 0% |
| 28/30-daymortality* | 7 | 6607 | 0.96(0.88 to 1.04) | 0.96 (0.88 to 1.04) | 0% | –0.01(–0.03 to 0.01) | –0.01(–0.03 to 0.01) | 0% |
| 90-daymortality | 2 | 2397 | 0.95(0.86 to 1.06) | 0.95(0.86 to 1.06) | 0% | –0.02(–0.06 to 0.02) | –0.02(–0.06 to 0.02) | 0% |
| <6 h | 2 | 1185 | 0.01(0.85 to 1.21) | 0.01 (0.85 to 1.21) | 0% | –0.01(–0.06 to 0.07) | –0.01(–0.06 to 0.07) | 0% |
| 6–24 h | 2 | 1828 | 0.94(0.83 to 1.06) | 0.93 (0.83 to 1.05) | 0% | –0.03(–0.08 to 0.02) | –0.03(–0.08 to 0.02) | 0% |
| The definition of sepsis | ||||||||
| ACCP/SCCM | 5 | 4477 | 0.94(0.86 to 1.03) | 0.94(0.86 to 1.04) | 0% | –0.02(–0.05 to 0.01) | –0.02(–0.05 to 0.01) | 0% |
| <6 h | 5 | 3251 | 0.93(0.83 to 1.03) | 0.93 (0.84 to 1.03) | 0% | –0.02(–0.06 to 0.01) | –0.03(–0.06 to 0.01) | 0% |
| 6–24 h | 5 | 3894 | 0.91(0.83 to 1.00) | 0.91 (0.83 to 1.00) | 0% | –0.03(–0.06 to 0.00) | –0.03(–0.06 to 0.00) | 0% |
| Non -ACCP/SCCM | 10 | 2506 | 0.93(0.78 to 1.12) | 0.96(0.81 to 1.14) | 4% | –0.01(–0.04 to 0.02) | –0.05(–0.11 to 0.01) | 27% |
| Severity of disease | ||||||||
| Sepsis | 2 | 658 | 1.10(0.77 to 1.57) | 1.10 (0.77 to 1.57) | 0% | 0.03(–0.09 to 0.14) | 0.03(–0.09 to 0.14) | 0% |
| Severesepsis | 7 | 2035 | 0.95(0.84 to 1.07) | 0.95 (0.85 to 1.07) | 0% | –0.02(–0.06 to 0.02) | –0.02(–0.06 to 0.02) | 0% |
| Septicshock | 3 | 1931 | 0.89(0.80 to 0.99) | 0.89 (0.80 to 0.99) | 0% | –0.04(–0.09 to 0.00) | –0.04(–0.09 to 0.00) | 0% |
RR, Relative Risk; 95% CI, 95% Confidence Intervals; RD, Risk difference; Fixed, fixed - effects model; Random, random - effects model.
*, 28/30 – day mortality were not stratified according to the time interval between patient enrollment and randomization in the ALBIOS study.
ACCP/SCCM, American College of Chest Physicians/Society of Critical Care Medicine.